The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV).
Until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown.